Stock Watch: Pfizer Caught Between The Pandemic And The Recovery
COVID-19 Gives …And It Takes Away, Disappointing Investors
The pandemic is bad for Pfizer’s hospital products and traditional vaccine sales – but recovery is less good for Comirnaty and Paxlovid. Were investors right to be underwhelmed by Pfizer’s 2022 projections?
